{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:28:18Z","timestamp":1763036898827},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,3,25]],"date-time":"2015-03-25T00:00:00Z","timestamp":1427241600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s00432-015-1963-9","type":"journal-article","created":{"date-parts":[[2015,3,24]],"date-time":"2015-03-24T08:24:28Z","timestamp":1427185468000},"page":"1689-1695","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Long-term follow-up of rituximab plus first-line mitoxantrone, chlorambucil, prednisolone and interferon-alpha as maintenance therapy in follicular lymphoma"],"prefix":"10.1007","volume":"141","author":[{"given":"Michael","family":"Herold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Rothmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Hirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Lakner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,25]]},"reference":[{"key":"1963_CR1","doi-asserted-by":"crossref","unstructured":"Buske C et al (2008) Rituximab in combination with CHOP in patients with follicular lymphoma: analysis of treatment outcome of 552 patients treated in a randomized trial of the German Low Grade Lymphoma Study Group (GLSG) after a follow up of 58\u00a0months Blood (ASH Annual Meeting Abstracts) 112:Abstract 2599","DOI":"10.1182\/blood.V112.11.2599.2599"},{"key":"1963_CR2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.2012.082412","volume":"98","author":"E Bachy","year":"2013","unstructured":"Bachy E et al (2013) Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma. Haematologica 98:1107\u20131114. doi: 10.3324\/haematol.2012.082412","journal-title":"Haematologica"},{"key":"1963_CR3","unstructured":"Buske C, Herold M, Willenbacher W, Dreyling M (2012) Follikul\u00e4res Lymphom (FL). DGHO-Onkopedia-Leitlinie. http:\/\/www.dgho-onkopedia.de\/de\/onkopedia\/leitlinien\/follikulaeres-lymphom#medikamentose-tumortherapie-protokolle . Zugriff am 2.9.2013"},{"issue":"Suppl 6","key":"1963_CR4","doi-asserted-by":"crossref","first-page":"vi59","DOI":"10.1093\/annonc\/mdr388","volume":"22","author":"M Dreyling","year":"2011","unstructured":"Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Group EGW (2011) Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6):vi59\u2013vi63. doi: 10.1093\/annonc\/mdr388","journal-title":"Ann Oncol"},{"key":"1963_CR5","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R et al (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 104:3064\u20133071. doi: 10.1182\/blood-2004-04-1323","journal-title":"Blood"},{"key":"1963_CR6","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14712598.2013.786698","volume":"13","author":"MM Griffin","year":"2013","unstructured":"Griffin MM, Morley N (2013) Rituximab in the treatment of non-Hodgkin\u2019s lymphoma\u2014a critical evaluation of randomized controlled trials. Expert Opin Biol Ther 13:803\u2013811. doi: 10.1517\/14712598.2013.786698","journal-title":"Expert Opin Biol Ther"},{"key":"1963_CR7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/jnci\/92.15.1240","volume":"92","author":"FD Groves","year":"2000","unstructured":"Groves FD, Linet MS, Travis LB, Devesa SS (2000) Cancer surveillance series: non-Hodgkin\u2019s lymphoma incidence by histologic subtype in the United States from 1978 through. J Natl Cancer Inst 92:1240\u20131251","journal-title":"J Natl Cancer Inst"},{"key":"1963_CR8","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M et al (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 25:1986\u20131992. doi: 10.1200\/JCO.2006.06.4618","journal-title":"J Clin Oncol"},{"key":"1963_CR9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W et al (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106:3725\u20133732. doi: 10.1182\/blood-2005-01-0016","journal-title":"Blood"},{"key":"1963_CR10","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/era.13.6","volume":"13","author":"ZM Li","year":"2013","unstructured":"Li ZM, Ghielmini M, Moccia AA (2013) Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. Expert Rev Anticancer Ther 13:313\u2013325. doi: 10.1586\/era.13.6","journal-title":"Expert Rev Anticancer Ther"},{"key":"1963_CR11","doi-asserted-by":"crossref","first-page":"4830","DOI":"10.1200\/JCO.2005.03.911","volume":"23","author":"TA Lister","year":"2005","unstructured":"Lister TA (2005) Improved survival for patients with follicular lymphoma. J Clin Oncol 23:4830\u20134831. doi: 10.1200\/JCO.2005.03.911","journal-title":"J Clin Oncol"},{"key":"1963_CR12","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1200\/JCO.2005.03.3696","volume":"24","author":"Q Liu","year":"2006","unstructured":"Liu Q et al (2006) Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25\u00a0years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J Clin Oncol 24:1582\u20131589. doi: 10.1200\/JCO.2005.03.3696","journal-title":"J Clin Oncol"},{"key":"1963_CR13","doi-asserted-by":"crossref","first-page":"54","DOI":"10.5581\/1516-8484.20120015","volume":"34","author":"S Luminari","year":"2012","unstructured":"Luminari S, Bellei M, Biasoli I, Federico M (2012) Follicular lymphoma\u2014treatment and prognostic factors. Rev Bras Hematol Hemoter 34:54\u201359. doi: 10.5581\/1516-8484.20120015","journal-title":"Rev Bras Hematol Hemoter"},{"key":"1963_CR14","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1200\/JCO.2007.13.5376","volume":"26","author":"R Marcus","year":"2008","unstructured":"Marcus R et al (2008) Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 26:4579\u20134586. doi: 10.1200\/JCO.2007.13.5376","journal-title":"J Clin Oncol"},{"key":"1963_CR15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood 107:265\u2013276. doi: 10.1182\/blood-2005-06-2508","journal-title":"Blood"},{"key":"1963_CR16","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1200\/JCO.2005.06.146","volume":"23","author":"AZ Rohatiner","year":"2005","unstructured":"Rohatiner AZ et al (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol 23:2215\u20132223. doi: 10.1200\/JCO.2005.06.146","journal-title":"J Clin Oncol"},{"key":"1963_CR17","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203\u20131210. doi: 10.1016\/S0140-6736(12)61763-2","journal-title":"Lancet"},{"key":"1963_CR18","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","volume":"112","author":"G Salles","year":"2008","unstructured":"Salles G et al (2008) Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 112:4824\u20134831. doi: 10.1182\/blood-2008-04-153189","journal-title":"Blood"},{"key":"1963_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"Salles G et al (2011) Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 377:42\u201351. doi: 10.1016\/S0140-6736(10)62175-7","journal-title":"Lancet"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1963-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-1963-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-1963-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T03:51:10Z","timestamp":1598845870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-1963-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,25]]},"references-count":19,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["1963"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-1963-9","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,25]]}}}